Dawson G, Johnson K, McCabe N R, Hancock L W
Department of Pediatrics, University of Chicago, IL 60637.
Neurochem Pathol. 1988 Jun;8(3):203-17.
The availability of specific antibodies and cDNA probes for lysosomal hydrolases has revealed unexpected heterogeneity among the human inherited lysosomal storage diseases. Using alpha-fucosidase and N-acetyl-beta-D-hexosaminidase deficiency variants as examples, it has been determined that a lysosomal hydrolase deficiency can result from DNA deletion mutations, failure to synthesize mRNA because of defective splicing, posttranslational defects in assembly, and synthesis of a precursor enzyme that is prematurely proteolytically degraded through lack of a protective protein. In some cases (fucosidosis), the different genotypes cannot be distinguished phenotypically, whereas in others (beta-hexosaminidoses) the phenotypes can range from infantile neurodegeneration through juvenile motor neuron disease to adult neurodysfunction. Biochemical studies on both diseases have revealed several distinct genotypes. We show that some forms of fucosidosis result from unstable enzyme that can be stabilized by protease inhibitors, whereas partial beta-hexosaminidase deficiencies cannot be corrected by these protease inhibitors.
针对溶酶体水解酶的特异性抗体和cDNA探针的可用性揭示了人类遗传性溶酶体贮积病中意想不到的异质性。以α-岩藻糖苷酶和N-乙酰-β-D-己糖胺酶缺乏变体为例,已确定溶酶体水解酶缺乏可能是由于DNA缺失突变、因剪接缺陷而无法合成mRNA、组装过程中的翻译后缺陷以及由于缺乏保护蛋白而导致的前体酶过早被蛋白水解降解。在某些情况下(岩藻糖苷贮积症),不同的基因型无法通过表型区分,而在其他情况下(β-己糖胺酶缺乏症),表型范围可从婴儿期神经退行性变到青少年运动神经元疾病再到成人神经功能障碍。对这两种疾病的生化研究揭示了几种不同的基因型。我们表明,某些形式的岩藻糖苷贮积症是由不稳定的酶引起的,蛋白酶抑制剂可以使其稳定,而部分β-己糖胺酶缺乏症不能通过这些蛋白酶抑制剂得到纠正。